|

HRS-5635 Injection (high dose) and Peg-IFN-α Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Fujian Shengdi Pharmaceutical Co., Ltd.1

Indications

  • Liver Disease1
  • Chronic Hepatitis b1

Other1 trial

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.